Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Early Out who wrote (1391)	4/22/1998 5:15:00 PM
From: Barron Von Hymen	Read Replies (2) \| Respond to of 9523

How does NYSE stocks trade?

To: Early Out who wrote (1391)	4/22/1998 5:15:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Invesco Fund Manager: Boomers Bolstering Drug Sector April 22, 1998 3:45 PM NEW YORK (Dow Jones)--Drug companies are benefiting from the aging of baby boomers, according to John Schroer, portfolio manager of the Invesco Strategic Health Sciences Fund. "We still feel very positive about the drug group overall," Schroer said in an interview on CNBC Wednesday afternoon. "From a macro standpoint the drug group is still benefiting from the baby boomers, who are all entering into the period of their lives where they start to take the most cardiovascular drugs and other depression drugs, and so forth." While the valuations of a few companies in the sector, including Pfizer Inc. (PFE) and Warner-Lambert Co. (WLA), are "a little higher than they have been historically," he said, the group as a whole is trading at "about a 40% premium on a multiple" to the overall market. "Historically that's well within the range of what's acceptable," he said. "And considering the superior growth potential of the group, we're still very comfortable with that." Schroer said he likes Pfizer, Warner-Lambert, SmithKline Beecham PLC (SBH) and ICN Pharmaceuticals Inc. (ICN).